Gsk Strengthens Its Commitment To Innovation And Growth With The Appointment Of Kevin Sin

Kevin Sin appointed as Head of Worldwide Business Development & Licensing at GSK

GSK strengthens its commitment to innovation and growth with the appointment of Kevin Sin

Sin brings a wealth of experience in business development and licensing to GSK, with a proven track record of success in the pharmaceutical industry

LONDON, April 18, 2018 – GlaxoSmithKline plc (GSK) today announced the appointment of Kevin Sin as Senior Vice President and Head of Worldwide Business Development & Licensing. Sin will join GSK on May 7, 2018 and will be based in London.

Sin has nearly three decades of broad industry experience, including 16 years at Novartis, where he held various leadership roles in business development and licensing. Most recently, he was Global Head of Business Development at Novartis, responsible for leading the company's global business development and licensing strategy. Prior to Novartis, Sin held roles at Amgen and McKinsey & Company.

Sin's appointment is a clear signal of GSK's commitment to innovation and growth. With his extensive experience in business development and licensing, Sin will play a key role in driving GSK's strategy to build a world-leading biopharmaceutical company.

"I am delighted to welcome Kevin to GSK," said Hal Barron, Chief Scientific Officer and President of R&D at GSK. "His deep understanding of the pharmaceutical industry and his proven track record of success in business development and licensing will be invaluable to GSK as we continue to build our pipeline and deliver innovative new medicines to patients."